Whitehawk Therapeutics, Inc. reported significant financial changes in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded no revenue for the period, a stark contrast to the $7.1 million generated in the same quarter of the previous year. This decline is attributed to the divestiture of its lead product, FYARRO, which was sold to KAKEN Investments in March 2025. Consequently, Whitehawk's net loss for the quarter was $22.2 million, compared to a net income of $73.0 million in the prior year, which was bolstered by a one-time gain from the sale of FYARRO.
Operating expenses for the first quarter of 2026 totaled $23.5 million, slightly higher than the $22.4 million reported in the same period of 2025. The increase was primarily driven by a substantial rise in research and development costs, which surged to $17.2 million from $8.8 million year-over-year. This increase reflects Whitehawk's strategic focus on advancing its pipeline of next-generation antibody-drug conjugates (ADCs), which are currently in clinical development. Selling, general, and administrative expenses decreased to $6.3 million from $12.8 million, largely due to reduced consulting and marketing costs following the divestiture.
In terms of operational metrics, Whitehawk's cash, cash equivalents, and short-term investments stood at $123.0 million as of March 31, 2026, providing a runway for ongoing operations into 2028. The company has shifted its focus to developing three ADC therapies targeting various cancer indications, with clinical trials for two of these therapies, HWK-007 and HWK-016, actively recruiting participants. The company anticipates data readouts from these trials in the first half of 2027.
Whitehawk's workforce has also undergone changes, with a restructuring plan implemented in 2024 that reduced its employee count by approximately 32%. This restructuring was part of a broader strategy to streamline operations and focus on its ADC pipeline. As of the latest filing, the company had 47.2 million shares outstanding, reflecting a slight increase from the previous quarter.
Looking ahead, Whitehawk Therapeutics aims to leverage its cash reserves to fund ongoing research and development activities, particularly for its ADC therapies. The company has indicated that it may seek additional financing through equity offerings or debt to support its strategic objectives, especially as it continues to incur significant operating losses. The management remains optimistic about the potential of its ADC portfolio to address unmet medical needs in oncology, positioning the company for future growth despite the current financial challenges.
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc. is an oncology-focused biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that target validated tumor antigens in solid and difficult-to-treat cancers. Leveraging advanced linker-payload technology and proprietary antibodies, Whitehawk aims to improve efficacy and safety by delivering potent Topoisomerase I inhibitor payloads directly to cancer cells. The company operates a virtual model, outsourcing clinical development and manufacturing, targeting global markets with high unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.